Lantus

Lantus

insulin glargine

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Insulin glargine
Indications/Uses
Adults, adolescents & childn ≥6 yr w/ DM where treatment w/ insulin is required.
Dosage/Direction for Use
Administer SC once daily at the same time everyday. Dose & timing of dose should be individually adjusted.
Contraindications
Special Precautions
Not the insulin of choice for the treatment of diabetic ketoacidosis. Switching a patient to another type or brand of insulin should be done under strict medical supervision & may require change in dose. Patients in whom hypoglycaemic episodes might be of particular clinical relevance eg, those w/ significant stenoses of coronary arteries or of blood vessels supplying the brain, & proliferative retinopathy particularly if not treated w/ photocoagulation. Patients w/ diminished warning symptoms of hypoglycaemia eg, those w/ marked improvement in glycaemic control, w/ gradual development of hypoglycaemia, elderly, after transfer from animal to human insulin, w/ autonomic neuropathy, long history of diabetes, psychiatric illness. Closely monitor patients & adjust dose, if necessary, in case of factors that increase susceptibility to hypoglycaemia eg, change in inj area, improved insulin sensitivity (eg, by removal of stress factors), unaccustomed, increased or prolonged physical activity, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, in hypothyroidism & in anterior pituitary or adrenocortical insufficiency). Intercurrent illness requires intensified metabolic monitoring. May cause insulin Abs to form. Concomitant use w/ other medicines. May impair ability to drive or operate machinery. Perform continuous inj site rotation. Monitor blood glucose after change in inj site & dose adjustment of antidiabetic. Renal & hepatic impairment. Pregnancy & lactation. Childn <6 yr.
Adverse Reactions
Hypoglycaemia. Lipohypertrophy, inj site reactions.
Drug Interactions
Enhanced blood glucose-lowering effect w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May potentiate/weaken blood glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Pentamidine may cause hypoglycaemia, sometimes followed by hyperglycaemia. Reduced/absent signs of adrenergic counter regulation w/ β-blockers, clonidine, guanethidine & reserpine.
MIMS Class
Insulin Preparations
ATC Classification
A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Lantus SoloStar pre-filled pen 100 u/mL
Packing/Price
1 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in